Motif Bio PLC

Receive alerts
Market Cap:
£686.77 k
0.14 GBX
52 weeks high
52 weeks low


Motif Bio is focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant bacteria. Our initial focus is on iclaprim, a targeted antibiotic with activity against MRSA.


Iclaprim is a targeted Gram-positive1 antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA). Iclaprim works in a different way than most other antibiotics and rapidly kills bacteria in vitro.



UK & US.


Graham Lumsden, Chief Executive Officer
Graham G. Lumsden, Chief Executive Officer of Motif, is responsible for all aspects of the strategy, management, and operations of the Company. Prior to joining Motif, Mr. Lumsden was a senior executive at Merck & Co., Inc. where he held commercial leadership positions in worldwide businesses including contraceptives and osteoporosis. Mr. Lumsden has a proven record of success leading change and delivering results in subsidiary and global leadership positions, including new product launches, pre-clinical/clinical development, regulatory strategy, cross-functional team leadership, IP strategy/litigation, and domestic/international sales and marketing. Mr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS), holds a postgraduate diploma from the Chartered Institute of Marketing (MCIM), and is a dual citizen of the U.S. and UK.

Jonathan E. Gold, Interim Chief Financial Officer
Mr. Gold has a history of senior financial positions and is currently Managing Director of JEG Capital Partners LLC, a family office and asset manager. He previously was a portfolio manager for the Federated Kaufmann Funds. Prior to that, Mr. Gold was a venture capitalist and was active in financing and building life sciences and technology companies. Mr. Gold received his B.S. and MBA in Finance from New York University’s Stern School of Business.

David Huang, M.D., Ph.D, Chief Medical Officer
Dr. Huang is a senior pharmaceutical research executive, and the former Chief Medical Officer at ContraFect Corporation. Dr. Huang also led a drug development group in anti-infectives at Pfizer. Dr. Huang has over 15 years of clinical, academic and research experience in infectious diseases. He has served as a faculty member at Baylor College of Medicine and currently as an adjunct Assistant Professor at Rutgers New Jersey Medical School. He continues to see patients at the Veterans Affairs Medical Center in Houston. His research interests include bacteriology and virology, especially the epidemiology, pathogenesis, and treatment of multi-drug resistant organisms. He is experienced in designing, executing and closing out Phase I – III clinical trials for both antibacterials and antiviral agents. Dr. Huang completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas at Southwestern and fellowship in infectious diseases at Baylor College of Medicine.  He is board-certified in both internal medicine and infectious diseases.

Motif Bio plc
201 Temple Chambers
3-7 Temple Avenue
London EC4Y 0DT
United Kingdom

Motif BioSciences Inc.
125 Park Avenue, 25th Floor
New York, NY 10017
United States
General: [email protected]
Investors: [email protected]

Ralph Corey, M.D.

Ralph Corey, M.D. is an Infectious Diseases Specialist, and he has served on the Duke University faculty since 1980 and became involved in clinical research at the Duke Clinical Research Institute in 2001 after 18 years as program director of the Internal Medicine Residency Training Program. He has over 30 years of experience in infectious disease research and during that time helped create the Staphylococcal aureus bacteremia group and the International Collaboration on Endocarditis (ICE). Dr Corey created and now directs the Hubert-Yeargan Center for Global Health at Duke University Medical Center. Dr. Corey, a professor of medicine and infectious diseases in the Duke University Medical Center, was recently named the Gary Hock Professor of Global Health. Dr. Corey’s clinical trial research focuses on Staphylococcus aureus infections including skin and soft tissue infections, hospital-acquired pneumonia, bacteremia and infectious endocarditis. Dr Corey has authored over 130 peer-reviewed publications and several book chapters.

Matthew Dryden, M.D., FRCPath

Matthew Dryden, M.D., FRCPath is an Infectious Diseases Specialist, and he serves as the Director of infection, Hampshire Hospitals, Winchester and University of Southampton, United Kingdom. Dr. Dryden trained at Oxford University from 1977 and St Thomas’ Hospital, London, and qualified in medicine in 1983. His clinical training was in and around London, with a 2-year period spent at Westmead Hospital in Sydney, Australia. Dr. Dryden is General Secretary of the British Society for Antimicrobial Chemotherapy.  He is a member of the Royal College of Physicians and Surgeons of Glasgow, the British Medical Association, the British Infection Society, the Hospital Infection Society, and a Fellow of the Royal Geographical Society and the Royal College of Pathologists.  His research interests have been in staphylococcal infection, the development of new antibiotics, the management of MRSA infections, and Lyme disease in the UK, and he has published and presented more than 100 papers in these fields.

Tom File, M.D., M.S.

Tom File, M.D., M.S. is an Infectious Diseases Specialist and Chairs the Division of Infectious Diseases at Summa Health System, Akron, Ohio, is Professor of Internal Medicine and Master Teacher, and the Chair of the Infectious Disease Section of Northeast Ohio Medical University (NEOMED). Dr. File is a highly respected and internationally recognized expert on infectious diseases including skin and skin structure infections and pneumonia. Previously, Dr. File served as Past-President and as a member of the Board of Directors for the National Foundation for Infectious Diseases and on the Board of Directors for the Infectious Disease Society of America. In 2010, he was elected as a Faculty Member to the Alpha Omega Alpha Honorary Society and in 2013, was recipient of the Watanakunakorn Clinician Award of the Infectious Diseases Society of America. Over the last 38 years, Dr. File has published over 275 original papers and numerous review articles and delivered some 145 presentations on various aspects of infectious diseases at scientific meetings throughout the USA and internationally. He currently, serves on the Editorial Boards of Infectious Diseases in Clinical Practice, where he is Editor-in-Chief; Infectious Disease News; plus the Journal of Microbiology and Immunology and Infection.

Thomas L. Holland, M.D., MSc-GH

Thomas Holland, M.D., M.Sc. is an infectious diseases specialist at Duke University, where he joined the faculty in 2010.  He also holds a faculty appointment at the Duke Clinical Research Institute.  His clinical trial research has focused on staphylococcal infections, particularly bacteremia and endocarditis, as well as skin and soft tissue infections, hospital-acquired and ventilator-associated pneumonia.  He has developed multiple trial protocols related to Gram-positive infections through his work with the Antibacterial Resistance Leadership Group and the Clinical Trials Transformation Initiative.  He was also the medical monitor for a recently completed multinational NIH-funded clinical trial examining treatment duration for staphylococcal bacteremia.

Thomas Lodise, Pharm.D, Ph.D.

Thomas Lodise, Pharm.D., Ph.D., is Professor at Albany College of Pharmacy and Health Sciences, Albany, New York. He is also an infectious diseases clinical pharmacy specialist at the Stratton VA Medical Center, Albany, New York.  Integrating his dual interests in research and patient care, his overall research goal is to quantitatively enhance our current understanding of antimicrobial exposure-response relationships in patients with invasive bacterial infections. His research encompasses three interrelated domains: pharmacokinetics (PK)/pharmacodynamics (PD), epidemiology, and outcomes.  His specific research objectives are 4-fold: develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs.  He has published over 110 peer-reviewed articles and is an editorial board member for Antimicrobial Agents and Chemotherapy, Pharmacotherapy, and Diagnostic Microbiology and Infectious Diseases.  He is a member of the vancomycin committees.  He is the current chair of the PK Special Emphasis Panel for the Antibacterial Resistance Leadership Group (ARLG), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

William D. O’Riordan, M.D.

William D. O’Riordan, M.D. is the founder and CEO of eStudy Sites, one of the pre-eminent network of clinical trial sites in the U.S. He is certified with the American Board of Emergency Medicine and is the lead investigator at the Chula Vista Research Site in California.  Dr. O’Riordan has held a number of clinical positions at the UCLA (University of California, Los Angeles) Medical Center and works at the Department of Emergency Medicine at the Sharp Chula Vista Medical Center. As a clinical trial Investigator at the eStudy Site at the Chula Vista Research Site, he has overseen numerous clinical trials with antibacterial agents at all stages of clinical development.

Antoni Torres, M.D.

Antoni Torres, M.D., is a Pulmonologist and he currently serves as the Head of the Respiratory Intensive Care Unit in the Department of Pneumology and Respiratory Allergy, Clinical Institute of the Thorax, Hospital Clinic of Barcelona.  He is Professor of Medicine at Faculty of Medicine at the University of Barcelona.  He received his degree in Medicine in 1977 from the Faculty of Medicine of the University of Barcelona.  Dr. Torres previously served as the director of the Clinic Institute of Pneumology and Thoracic Surgery; Head of the Department of Pneumology and Respiratory Allergy of the Hospital Clinic of Barcelona; Chief of Respiratory Intensive Care Unit. He currently is Coordinator of all the ICUs of the Clinic Thorax Institute; National and international physician of reference for several pulmonary conditions. Dr. Torres has published over 350 original articles. Dr. Torres has also served previously as President of the area of tuberculosis and respiratory infections of the Spanish Society of Pneumology; President of the area of respiratory infections of the Latin American Thorax Association (ALAT); Chairman of the Respiratory Intensive Care Assembly of the European Respiratory Society; Vice President of Spanish Society of Pneumology and Thoracic Surgery; Chairman of the “Microbiology and Tuberculosis Pulmonary Infections” Assembly of the American Thoracic Society.

Marc Wilcox, M.D.

Marc Wilcox, M.D. is a Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds (Leeds Institute of Molecular Medicine), and is the Lead on Clostridium difficile for the Public Health England.  He has formerly been the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT. Professor Wilcox is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection Committee and is a member of the HPA’s Programme Board on Healthcare Associated Infection & Antimicrobial Resistance.  He is an advisor to the Department of Health in England on healthcare associated infections (HCAIs), the Technology Strategy Board on HCAI diagnostics, the UK EPIC/NICE projects, the Health Technology Assessment programme on Healthcare Associated Infection, the Wellcome Trust on novel antimicrobials, and the European Centre for Disease Control.  Professor Wilcox’s research team’s projects include several areas of healthcare associated infection, in particular Clostridium difficile infection, staphylococcal infection, and the clinical development of new antimicrobial agents.  He has authored more than 320 papers and published a number of books and chapters.

Please click here for further information